: The strategic plan of the University of Kentucky (UK) P30 application in response to RFA-OD-09-005 is to provide support for the recruitment of 2 junior investigators who will be immersed into a highly collaborative, interdisciplinary group of investigators focused on the diagnosis, prevention and treatment of gastrointestinal (Gl) cancers. This productive group consists of basic and clinical scientists, including molecular and cell biologists, clinician-scientists (surgeons, gastroenterologists, and medical oncologists), Gl pathologists, epidemiologists, biostatisticians and investigators in the School of Pharmacy with successful programs in drug design and delivery. The purpose of this program is to support promising junior investigators who will participate in translational Gl cancer research projects as part of our recently-funded P20 program (P20 CA127004) which provides support for the development of a fully-funded P50 Gl cancer SPORE application. Our goal is to develop a cadre of future Gl cancer investigators who can participate at the intersection of molecular biology, drug discovery and clinical care to become leaders in integrative and team approaches to understand the complex issues of Gl cancer as it relates to potential prevention and treatment strategies. This proposal builds upon the momentum and existing strengths at the Markey Cancer Center and is further supported by substantial institutional, state and philanthropic support.

Public Health Relevance

Although tremendous strides have been made towards understanding the basic biology of Gl cancers, very few of these advances have been translated into improved outcomes for patients. To accelerate translation of scientific advances into improved clinical outcomes, it is necessary that an investigator function effectively as part of a multidisciplinary team. The goal of this proposal is to develop talented junior investigators into productive academic Gl investigators.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
1P30CA147886-01
Application #
7859513
Study Section
Special Emphasis Panel (ZCA1-PCRB-G (O9))
Program Officer
Lei, Ming
Project Start
2009-09-30
Project End
2011-08-31
Budget Start
2009-09-30
Budget End
2010-08-31
Support Year
1
Fiscal Year
2009
Total Cost
$715,228
Indirect Cost
Name
University of Kentucky
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
939017877
City
Lexington
State
KY
Country
United States
Zip Code
40506
Ye, Q; Cai, W; Zheng, Y et al. (2014) ERK and AKT signaling cooperate to translationally regulate survivin expression for metastatic progression of colorectal cancer. Oncogene 33:1828-39
Xiong, Gaofeng; Wang, Chi; Evers, B Mark et al. (2012) RORýý suppresses breast tumor invasion by inducing SEMA3F expression. Cancer Res 72:1728-39
Du, Jun; Xu, Ren (2012) ROR?, a potential tumor suppressor and therapeutic target of breast cancer. Int J Mol Sci 13:15755-66
Xu, Ren; Mao, Jian-Hua (2011) Gene transcriptional networks integrate microenvironmental signals in human breast cancer. Integr Biol (Camb) 3:368-74